 "remdesivir, coronavirus, drugs, covid, pharma")
Drug firm Jubilant Life Sciences on Monday said it has launched the generic version of antiviral drug remdesivir in India for the treatment of Covid-19 patients.
The injectable drug, under the brand name 'JUBI-R', is priced at Rs 4,700 per vial of 100 mg.
The company will make the drug available to over 1,000 hospitals providing Covid-19 treatment, Jubilant Life Sciences said in a statement.
In order to increase the accessibility of the drug to patients below the poverty line and to front-line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of the Jubilant Group, is launching programs in India aimed at its
